Remdesivir News and Research

RSS

SARS-CoV-2 infects human embryonic epithelial and lung cells

As COVID-19 continues to spread the world over, investigators are still trying to understand how it ravages the human body. A recent study published on the preprint server bioRxiv in September 2020 shows that the virus is capable of infecting human embryonic cells that are destined to form the epithelial surfaces of the body, both internal and external, as well as lung cells.

29 Sep 2020

SARS-CoV-2 re-infection is real but rare: Case study

Now, American researchers have looked at all reported cases of re-infection and the possible reasons behind them. Their study titled, “Re-infection with SARS-CoV-2 and Failure of Humoral Immunity: a case report,” is published online on the preprint server medRxiv in September 2020.

28 Sep 2020

Special formulation of inhaled niclosamide may be effective against SARS-CoV-2

Now in new research published on the preprint server bioRxix*, a novel formulation of the drug Niclosamide (NIC) is observed to be effective against SARS-CoV-2 and MERS-CoV in mouse models; it also protects against methicillin-resistance Staphylococcus aureus pneumonia and inflammatory lung damage.

28 Sep 2020

Prevalence of SARS-CoV-2 with D614G mutation in a second wave infection in Houston

A recent study reveals that the genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detected in the initial phase of coronavirus disease 2019 (COVID-19) pandemic differ from the variants detected in a massive second wave of infection in Houston, Texas. The study is currently available on the medRxiv preprint server.

24 Sep 2020

These secret safety panels will pick the COVID vaccine winners

Most Americans have never heard of Dr. Richard Whitley, an expert in pediatric infectious diseases at the University of Alabama-Birmingham.

24 Sep 2020

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

A recent study published on the preprint server bioRxiv* in September 2020 shows the value of drug combinations to enhance the therapeutic and preventive efficacy of such repositioned drugs in standard antiviral therapy.

20 Sep 2020

Scientists investigate active plasma metabolite of remdesivir in SARS-CoV-2 mouse model

Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.

20 Sep 2020

Animal data supports efficacy of baricitinib vs SARS-COV-2

The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 2020 reports on the characteristics of the drug baricitinib when used as monotherapy to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

New drug candidate suppresses SARS-CoV-2 replication

Researchers at Stanford University and Utah State University have developed a novel inhibitor of the coronavirus main protease (Mpro) that effectively suppresses the viral replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

Pfizer's anti-viral 3CL protease inhibitor shows antiviral potential against SARS-CoV-2

Now, a new study by researchers from Pfizer, University of Arizona, Purdue University, The Scripps Research Institute, and UC San Diego School of Medicine and published on the preprint server bioRxiv in September 2020 reports that an enzyme inhibitor may act in synergism with the approved antiviral remdesivir to suppress viral replication in COVID-19.

16 Sep 2020

New book gives overview of viruses and how they emerge to cause pandemics

Since the novel coronavirus SARS-Cov-2 emerged late last year, it has been virtually impossible to consume any news without encountering stories about the virus and how it spreads, potential treatments, and the development of new vaccines.

11 Sep 2020

Existing drug masitinib identified as potential inhibitor of SARS-CoV-2

Researchers in the United States have demonstrated that a drug originally developed as a treatment for cancer exhibits antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

2 Sep 2020

Health officials worry nation is not ready for COVID-19 vaccine

Millions of Americans are counting on a COVID-19 vaccine to curb the global pandemic and return life to normal.

2 Sep 2020

14 existing drugs identified as SARS-CoV-2 main protease inhibitors

Now, a new study published on the preprint server bioRxiv in August 2020 reports on the identification of 14 compounds that can inhibit the key viral enzyme called the Main Protease (MPro) at micromolar concentrations.

1 Sep 2020

Cat antiviral that inhibits SARS-CoV-2 fast-tracked for human clinical trials

Now, a team of researchers at the University of Alberta in Canada has identified viral inhibitors that they claim are potential candidates as a treatment for COVID-19. The team is set to launch clinical trials of the drug that is used as a treatment for a type of coronavirus in cats.

31 Aug 2020

New lipid derivatives of Remdesivir have higher anti-coronavirus activity

In a fascinating new preprint paper published on bioRxiv* in August 2020, the researchers report “the synthesis and antiviral evaluation of three novel lipophilic prodrugs of RVn-monophosphate that are substantially more active than Remdesivir in cells infected with SARS-CoV-2.” These could be of immense use in treating COVID-19 patients early and helping to end transmission.

30 Aug 2020

Scientists describe known approaches for treatment of SARS-CoV-2 infection

Researchers from Sechenov University together with Russian and Iranian colleagues described currently known approaches to the treatment of SARS-CoV-2 infection.

29 Aug 2020

Mouse-adapted SARS-CoV-2 model helps advance the development of COVID-19 vaccines

A new COVID-19 mouse model developed at the University of North Carolina at Chapel Hill captures many of the features of human disease and has helped advance a COVID-19 vaccine candidate to clinical trial.

27 Aug 2020

5 things to know about convalescent blood plasma

President Donald Trump told the American people this week that convalescent plasma is a potential new treatment for COVID-19.

27 Aug 2020

Scientists identify two markers of inflammation that predict severity of COVID-19 cases

Mount Sinai scientists have identified two markers of inflammation that reliably predict the severity of COVID-19 cases and likelihood of survival, providing a foundation for a diagnostic platform and therapeutic targets, according to a study published in Nature Medicine in August.

25 Aug 2020